Proteins and Peptides
26 February 2015
DS Healthcare Announces Discovery Of New Peptide26 February 2015
Sanofi Receives FDA Approval of Once-Daily Basal Insulin Toujeo®23 February 2015
FDA Accepts BLA Filing For Synageva’s Kanuma™ (Sebelipase Alfa); Grants Priority Review And Assigns PDUFA Date20 February 2015
Novo Nordisk announces positive results for phase 2 trial with oral semaglutide in people with type 2 diabetes18 February 2015
Apotex Announces FDA Has Accepted For Filing its Biosimilar Application for Filgrastim (Grastofil™)17 February 2015
Dipexium Pharmaceuticals Announces Successful Completion and Initial Results of Phase 1 Skin Sensitization Trial of Locilex®17 February 2015
Stealth BioTherapeutics Initiates a Clinical Study of Bendavia for the Treatment of Orphan Mitochondrial Diseases13 February 2015
Horizon Pharma plc Submits Investigational New Drug Application for ACTIMMUNE(R) in the Treatment of Friedreich’s Ataxia13 February 2015
Genzyme Presents Data from its Phase 1b Program for Niemann-Pick Type B at the Lysosomal Disease Network’s WORLD Symposium 201512 February 2015
Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clinical Data on PRX-102 for Fabry Disease at the WORLD Symposium12 February 2015
Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p5312 February 2015
Genzyme Presents Phase 3 Clinical Trial Extension Results for Cerdelga® (eliglustat) at Lysosomal Disease Network’s WORLD Symposium 201510 February 2015
Amicus Therapeutics Presents Preclinical Data on Next-Generation Pompe ERT at WORLDSymposium(TM) 20157 February 2015
European Commission approves additional indication for VELCADE® (bortezomib) in mantle cell lymphoma5 February 2015
Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet5 February 2015
Helsinn and Zealand Announce the Advance of Elsiglutide into Phase IIB Development for the Prevention of Chemotherapy-Induced Diarrhea5 February 2015
U.S. FDA Accepts for Review CSL Behring’s Biologics License Application for rIX-FP for Hemophilia B Patients4 February 2015
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX in Advanced Gastrointestinal MalignanciesNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports